Bristol Myers Squibb Says FDA Accepts Snda For Camzyos As Potential Treatment For Adolescents With Symptomatic oHCM; PDUFA Date Set September 30

Loading news article.

Bristol Myers Squibb Says FDA Accepts Snda For Camzyos As Potential Treatment For Adolescents With Symptomatic oHCM; PDUFA Date Set September 30 | WAPE

Bristol Myers Squibb Says FDA Accepts Snda For Camzyos As Potential Treatment For Adolescents With Symptomatic oHCM; PDUFA Date Set September 30

Article summary

Related companies

Comments —